title: Direct interaction of PU.1 with oncogenic transcription factors reduces its serine phosphorylation and promoter binding.
abstract: The homeostasis of hematopoiesis in the bone marrow is governed by a small number of key transcription factors, including PU.1, GATA-1 and c/EBPα. PU.1, a member of the E-twenty-six family of transcription factors, is indispensable for normal hematopoiesis. Inactivation of PU.1 induces acute leukemia in mice. Recent data suggest that the leukemia-associated fusion protein pro-myelocytic leukemia/retinoic acid receptor alpha (PML/RARα) inhibits PU.1, but the mechanism mediating this inhibition is unclear. Here, we investigated the mechanisms by which the fusion proteins PML/RARα and pro-myelocytic leukemia zinc finger/RARα (PLZF/RARα) (X-RARα) interfere with the function of PU.1. We found that X-RARα proteins functionally inactivate PU.1 by reducing its promoter-binding capacity, resulting in a reduction in PU.1-dependent transcriptional transactivation. In fact, X-RARα proteins directly interact with PU.1, leading to both the sequestration of PU.1 from its target promoters and a reduction in its serine phosphorylation, which is crucial for its promoter binding and transcriptional activity. We found that the functional inactivation of PU.1 could be overcome by the forced overexpression of PU.1 in PML/RARα- or PLZF/RARα-positive murine hematopoietic progenitor cells; evidently, this overexpression rescued the leukemic differentiation block induced by X-RARα proteins. Our data thus provide strong evidence that X-RARα proteins functionally inhibit PU.1, shedding light on the mechanism by which X-RARα proteins induce leukemogenesis.
authors: Department of Hematology, Goethe-University, Frankfurt, Germany.
authors: A
authors: A
authors: Seshire
authors: T
authors: T
authors: Rößiger
authors: M
authors: M
authors: Frech
authors: S
authors: S
authors: Beez
authors: H
authors: H
authors: Hagemeyer
authors: E
authors: E
authors: Puccetti
mesh_terms: D000818:Animals; D015153:Blotting, Western; D002454:Cell Differentiation; D002478:Cells, Cultured; D047369:Chromatin Immunoprecipitation; D005455:Fluorescent Antibody Technique; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000378:metabolism; D047468:Immunoprecipitation; D015473:Leukemia, Promyelocytic, Acute / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D015514:Oncogene Proteins, Fusion / Q000235:genetics / Q000378:metabolism*; D010766:Phosphorylation; D011401:Promoter Regions, Genetic / Q000502:physiology*; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012694:Serine / Q000737:chemistry* / Q000378:metabolism; D015534:Trans-Activators / Q000235:genetics / Q000378:metabolism*; D000099232:Proto-Oncogene Protein Spi-1
chemical_list: D015514:Oncogene Proteins, Fusion; D011518:Proto-Oncogene Proteins; D012333:RNA, Messenger; D012694:Serine; D015534:Trans-Activators; D000099232:Proto-Oncogene Protein Spi-1; C492209:PLZF-RARalpha fusion protein, mouse; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein